Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

NCT02813837 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, B-Cell
Lymphoma, B-Cell

Interventions

BIOLOGICAL: CD19CART

Sponsor

Innovative Cellular Therapeutics Co., Ltd.